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Characteristics and quality of life of patients
presenting to cancer support centres: patient
rated outcomes and use of complementary
therapies
Bonnie J Furzer1,2*, Kemi E Wright1, Anna S Petterson2,4, Karen E Wallman1, Timothy R Ackland1
and David JL Joske1,2,3
Abstract
Background: In order to effectively target and provide individualised patient support strategies it is crucial to have
a comprehensive picture of those presenting for services. The purpose of this study was to determine the
characteristics and patient rated outcomes of individuals presenting to SolarisCare cancer support centres and their
choices regarding complementary and integrated therapies (CIT).
Methods: A cohort with a current or previous cancer diagnosis aged 18 – 87 years presenting to a SolarisCare
centre during a 5-day period completed a questionnaire. Four SolarisCare centres participated in the trial including
regional and metropolitan locations. Outcomes included medical and demographic characteristics, CIT variables and
patient rated outcomes (PROs) including quality of life (QoL).
Results: Of the 95 participants (70.3%) who completed the survey, the mean age was 60.5 years with 62% currently
receiving treatment. Eighty percent of the sample had at least one other comorbid condition, with the most
popular CIT being relaxation massage. Of the PROs, QoL was significantly lower than norms for the Australian
population and other mixed cancer populations. No notable differences were seen between genders, however
significantly poorer outcomes were found for the younger age group. Fifty percent of the population did not meet
physical activity recommendations, and musculoskeletal symptoms explained between 25-27% of variance in QoL.
Conclusions: A greater understanding of the health profiles of patients presenting to supportive care centres and
their use of CIT, provides Western Australian health professionals with key information to ensure the safety of
supportive care practices, as well as fosters optimal patient outcomes and enhances the integration of supportive
care strategies within mainstream medical care.
Keywords: Cancer patients, Complementary therapies, Quality of life, Supportive care, Symptom distress
Background
Cancer is one of the largest contributors to mortality
and morbidity in Australia accounting for 19% of the
total burden of disease and 12.5% of deaths worldwide
[1]. There were 108,363 new cases of cancer diagnosed
in Australia in 2007, with the lifetime risk of diagnosis
below the age of 85 at 1 in 2 [1]. Concurrently, advances
in early diagnosis and treatment have seen increases in
survival rates with cancer patients accounting for ap-
proximately 3.2% of the Australian population, with a
predicted growth rate of 2% annually [2]. Support ser-
vices have emerged as an integral aspect of patient man-
agement during and post treatment, with interventions
ranging from pharmacological to lifestyle modification,
and branching out to complementary integrated therap-
ies (CIT). With 63% of cancer patients’ alive 5 years post
treatment, targeted services are crucial to help manage
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long-term medical and psychosocial health, including
quality of life (QoL), fatigue and pain [1].
Cancer is most prevalent in Australians over 65 years
of age, affecting 11% of males and 4% of females [3]. The
combination of age related decline, comorbidites and the
side effects of multiple treatments creates a population
with unique characteristics and specific health needs.
While fear of recurrence and development of secondary
cancers are the biggest concerns for patients one year
post diagnosis, a study by Baker and colleagues found
67.1% of patients were also concerned about a physical
health problem, such as fatigue and loss of strength [4].
Research has consistently shown that cancer patients
have low or reduced levels of QoL from initial diagnosis
often for several years post-treatment, in addition to
significant psychological distress commonly manifested
as depression and/or anxiety [5]. Also occurring during
treatment and often persisting 5–10 years post treatment
is cancer related fatigue (CRF), considered one of the most
debilitating symptoms, affecting 70-100% of patients [6].
In addition to CRF, musculoskeletal symptoms have been
widely documented in both patients and survivors [7],
with strong associations between symptoms such as joint
and muscle pain, and weakness and fatigue [8].
A study of supportive care strategies across six coun-
tries, including Australia, reported 35-60% of adults have
used some type of non-conventional treatment or ther-
apy [9]. In Australia, the use and prevalence of CIT is in-
creasing with an estimated $2.3 billion spent in 2000
[10]. In 1996, CIT use amongst a cancer population was
reported to be 21.9%, with 75% having tried more than
one therapy and remarkably 40% not discussing usage
with their physician [11]. The most common motiva-
tions for using CIT are to relieve symptoms/side effects,
assist in disease management, improve immunity, im-
prove QoL and increase sense of control [12,13].
With the increased utilisation of support strategies
including CIT, there is a crucial need to identify the
characteristics of those presenting to a cancer support
centre. SolarisCare is a unique cancer support organisa-
tion in Australia, offering drop-in centres, mostly within
hospital settings, that provide a quiet area, access to in-
formation, and a range of CIT for cancer patients and
carers. These sessions are carefully supervised and thera-
pists are selected to ensure patients’ physical and psycho-
logical safety; no adverse medical events have occurred in
11 years’ of practice.
An increased understanding of cancer patients cur-
rently accessing CIT and supportive care services enables
the refinement of patient needs and allows the tailoring
and specificity of services to achieve optimal patient care
and outcomes. Therefore, the aim of this study was to
determine medical and demographic characteristics and
patient rated outcomes (PROs) of individuals receiving
CIT at SolarisCare cancer support centres in Western
Australia.
Methods
The study was conducted over a five-day period at four
SolarisCare cancer support centres spread throughout the
South West and Greater Southern regions of Western
Australia. The data from this study forms part of a
broader study, which was granted ethics approval by The
University of Western Australia’s Human Research Ethics
Committee (RA/4/1/2113) and the Human Ethics & Re-
search Committee at Sir Charles Gairdner Hospital (Ref.
2009–61). Written informed consent was obtained from
all participants and eligibility requirements for the study
included the ability to provide informed consent; a diag-
nosis of cancer; and presentation to a SolarisCare centre
with the intent to receive services.
Demographic and medical questions were designed
based on previous research and patient information sheets
currently in use at SolarisCare (Additional file 1). Add-
itionally, participants completed a questionnaire package
that assessed quality of life using the Functional Assess-
ment for Cancer Therapy (FACT-G) [14] and the Short
Form 36 Health Survey (SF-36) [15]. Fatigue was mea-
sured using the Schwartz Cancer Fatigue Scale (SCFS)
[16]; musculoskeletal symptoms were measured with the
Muscle Joint Measure (MJM) [8]; and physical activity was
measured using the International Physical Activity Ques-
tionnaire (IPAQ) [17]. The reliability and validity of all the
scales used has previously been established, with these
scales widely utilised in cancer research.
Statistical analysis
All analyses were conducted using SPSS® software, version
19. Outcome variables were categorised and analysed, and
cross tabulations of CIT by demographic and clinical
variables were constructed. Preliminary descriptives were
performed on all PROs to ensure no violation of the
assumptions of normality, linearity and homoscedasticity,
with independent sample t-tests used to assess differences
between groups and Pearson correlations used to explore
the relationship between variables.
Results
Participant characteristics and CIT use
Of the 135 eligible participants, 95 (70.3%) agreed to
participate, with 46% (n = 44) recruited from Sir Charles
Gardiner Hospital, 25% (n = 24) from St John of God,
18.9% (n = 18) from Bunbury and 9.5% (n = 9) from
Albany. The patients’ characteristics and medical infor-
mation are provided in Table 1. Forty three percent of
the population had metastases. The most comon sites
were bone (37.5%; n = 15), liver (35%; n = 14) and lung
(27.5%; n = 11). Of the participants, 62% (n = 59) were
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currently receiving treatment with 66% (n = 39) receiving
radiotherapy, 32% (n = 19) chemotherapy, and 22% (n =
13) hormone therapy. Additionally, 70% (n = 63) had
undergone a cancer related surgery. Forty percent of
participants (n = 38) reported one other comorbidity,
24.2% (n = 23) had 2–3, 15.8% (n = 15) had greater than
4, with only 20% (n = 19) presenting with none. The
types of comorbidities are shown in Figure 1.
The total number of CIT sessions attended by partici-
pants was variable with 43.2% (n = 41) attending less
than 6 sessions, 21.1% (n = 20) between 6 and 12 sessions,
25% (n = 24) greater than 12 and 10.5% (n = 10) not
providing data. Additionally, participants recorded the
number of different therapies utilised, with 31.6% (n = 30)
trying 1–2 therapies, 31.6% (n = 30) 3–4 therapies and
25.4% (n = 24) greater than five therapies. The types of
CIT used by participants are shown in Figure 2.
Patient rated outcomes
There were statistically no significant differences in FACT-
G (72.9 ± 17.7, t = −0.293, p = 0.770) and SCFS (15.1 ± 6.1,
t = −1.498, p = 0.138) scores between the population under
study and those of other mixed cancer. However, the MJM
and SF-36 scores, when compared to Australian based
norms [15] or other mixed cancer populations [8,18,19]
showed a number of statistically significant differences
illustrated in Table 2. Differences were evident in the range
and median ages of the SF-36 mixed cancer sample
(median age = 44.2, range 18–77, female 73%, male 27%),
which may account for some of the variation.
Analyses of scores recorded on the SF-36 showed no
significant differences between male and females in the
Physical Component Score (PCS; Male 41.14 ± 11.20; Fe-
male 40.78 ±10.34; t = 0.377, p = 0.88) or in the Mental
Component Score (MCS; Male 43.34 ± 10.43; Female
41.35 ± 13.39; t = 0.237, p = 0.47). However, scores on the
General Health (GH) subscale were significantly lower for
males compared to females (Male 38.88 ± 11.86; Female
44.52 ± 11.78; t = −2.183, p = 0.03). Results showed the
MCS was significantly lower for those ≤ 62 years (39.67 ±
12.13) compared to those aged ≥ 63 years (44.58 ± 12.48;
t = −1.943, p = 0.05). In addition, there was a significant
difference for Social Functioning (SF; Age ≤ 62 n = 34.81,
SD = 12.17; Age ≥ 63 n = 41.82, SD = 11.92; t = −2.828, p =
0.006) with lower scores for the younger age group. When
exploring the FACT-G and its subscales, social wellbeing
(SWB), functional wellbeing (FWB) and total FACT-G
scores were all significantly lower for those ≤ 62 years,
shown in Table 3.
Inter-correlations between the MJM total score and
subscales were medium to large in sizes, with all values for
r ≥ 0.30 (Table 4). A strong negative relationship was shown
between the PCS as measured by the SF-36, and musculo-
skeletal symptoms measured by the MJM (r = −0.501, n =
92, p = <.001), with high levels of symptoms associated with
lower levels of physical functioning. Independently, 3 of the
4 subscales of the MJM showed moderate to strong nega-
tive relationships with PCS and its subscales (Table 5). Add-
itionally, there was a strong negative correlation between
Physical Wellbeing (PWB) measured by the FACT-G and
Table 1 Demographic and medical characteristics of
study participants
Variable n = 95 Variable n = 95
Demographic
profile
Medical profile
Gender Cancer site
Male 33 (34.7%) Breast 22 (23.2%)
Female 62 (65.2%) Gynaecological 11 (11.6%)
Age (±SD; range) 60.49
(12.65; 28–87)
Colorectal 9 (9.5%)
25-34 1 (1.1%) Prostate 8 (8.4%)
35-44 10 (10.5%) Kidney 4 (4.2%)
45-54 23 (24.2%) Lung 6 (6.3%)
55-64 20 (21.1%) Haematological 7 (7.4%)
65-74 28 (29.5%) Head and neck 6 (6.5%)
75+ 13 (13.7%) Brain 6 (6.3%)
Employment Melanomas 4 (4.2%)
Not employed 13 (13.7%) Pancreatic 3 (3.2%)
Casual 5 (5.3%) Bone 3 (3.2%)
Part time 10 (10.5%) Stomach 1 (1.1%)
Full time 3 (3.2%) Don’t know 5 (5.3%)
Sick Leave 19 (20.0%) Allied health
professionals
consulted
Months on sick
leave (±SD;
range)
6.55
(4.17; 0.5-16)
Psychologist/
counsellors
23 (24.2%)
Retired 45 (47.4%) Physiotherapy/
chiropractic
13 (13.7%)
Retired since
diagnosis
19 (20%) Yoga/pilates/exercise 11 (11.6%)
Physical activity
level
n = 92 Medical specialist 11 (11.6%)
Low 48 (52.2%) Support group 10 (10.5%)
Moderate 36 (39.1%) Naturopath/herbalist 10 (10.5%)
High 8 (8.7%) Dietician/nutritionist 8 (8.4%)
Days of activity Supplement use 62 (65.9%)
< 5 days a
week
46 (50%) Self-selected 27 (28.4%)
≥ 5 days a
week
46 (50%) Prescribed 23 (24.2%)
Self-selected and
prescribed
12 (12.6%)
Don’t know 1 (1.1%)
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musculoskeletal symptoms, including weakness (r =−0.548,
n = 91, p < 0.001), myalgias (r = −0.518, n = 91, p < 0.001),
and arthralgias (r = −0.398, n = 91, p < 0.001), as measured
by the MJM (r = −0.521, n = 92, p < 0.000).
Discussion
With the two major SolarisCare centres being located
within treating hospitals it is not surprising that 62% of
the study population were currently receiving treatment.
This highlights the crucial need for continual communi-
cation with doctors and specialists. Seventy percent of
patients reported using supplements, with a large por-
tion self-selecting their supplements. This raises consid-
erable concerns about the potential for toxic interactions
with conventional treatments and the potential lack of
disclosure to doctors. Communication between patient
and doctors on CIT use had been shown to be poor [12]
with lack of education of both nurses and doctors [13],
as well as a lack of protocols and guidelines being the
biggest barriers to communication.
This study had a higher percentage of women (65.2%)
compared to men (34.7%), which may suggest that
Figure 1 Percentage of comorbidities of study participants (n = 95). % of sample.
Figure 2 Frequency of complementary therapy use (n = 95). % usage.
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SolarisCare centres were not considered as appealing by
male cancer patients or may reflect the large breast can-
cer practice at one hospital in particular. With equally
high rates of cancer in males, it is important for support
services to be directed towards men and the medical
professionals involved in their treatment. This should
be considered in future research and service provision.
As shown in previous research, the cancer population
described in this study exhibited significantly lower scores
on PROs compared to the general population [5,15],
additionally a number of variables were also significantly
lower than in a mixed cancer population [8,14,18,19]. It is
notable that only one variable, GH, showed a statistically
significant difference between males and females. How-
ever, due to the greater proportion of women this study
was not adequately powered to comprehensively examine
gender differences and future reseach should investigate
the impact of gender further.
Investigation of the impact of age demonstrated those
in the younger cohort (≤ 62) were found to have signifi-
cantly worse outcomes than older patients. This is in
accord with research by Baker and colleagues (2005)
who found more problems reported by younger survivors
(18–54 years) [4]. Researchers have previously attributed
the discrepancies between younger and older cancer pa-
tients to a number of factors including increased demand
on younger patients in terms of social and economic
variables, and a difference in the perception or expectation
of health and QoL as reflected in subjective assessment
[4,20]. Future research should investigate this relationship
further through the utilisation of subjective and objective
measures which provide age matched normative values.
It is encouraging that the data suggests those who are
in need of support services are accessing the resources
available at SolarisCare whether through recommendation
by health professionals, other patients or self-selected.
Table 2 Patient rated outcomes compared with mixed cancer and Australian population norms
Snapshot study Means of other cancer pop. AUS. ABS. general population
n Mean ± SD n Test value t p Test value t p
Physical component score 95 40.90 ±10.60 1183 45.15 −3.91 <0.001** 49.70 −8.09 <0.001**
Physical functioning 95 60.67 ±24.96 1183 77.27 −6.48 <0.001** 82.5 −8.53 <0.001**
Role physical 95 45.42 ±28.15 1183 45.42 -.001 .999 79.8 −11.90 <0.001**
Vitality 95 43.22 ±21.76 1183 55.53 −5.51 <0.001** 64.5 −9.53 <0.001**
General health 95 42.68 ±12.04 1183 61.38 −2.28 0.025* 71.6 −6.22 <0.001**
Mental component score 95 42.00 ±12.48 1183 49.94 −6.20 <0.001** 50.10 −6.38 <0.001**
Bodily pain 95 60.94 ±28.05 1183 65.99 −1.75 0.82 76.8 −5.51 <0.001**
Social functioning 95 57.10 ±28.63 1183 76.08 −6.46 <0.001** 84.9 −9.46 <0.001**
Role emotional 95 61.05 ±28.77 1183 70.58 −3.23 0.002* 82.8 −7.37 <0.001**
Mental health 95 66.26 ±21.28 1183 73.04 −3.10 0.003* 75.9 −4.41 <0.001**
Muscle joint Measure 91 1.19 ±0.85 317 0.94 2.78 0.007*
Cramps 91 0.97 ±0.91 317 0.93 .472 .638
Weakness 91 1.27 ±1.09 317 0.81 3.98 <0.001**
Myalgias 91 1.25 ±1.17 317 1.10 1.21 .229
Arthralgias 91 1.27 ±1.18 317 0.98 2.36 .020*
Results are mean ± SD (n = 95).
* p < .05, **p < .001 2-tailed.
Table 3 Examination of FACT-G and subscales by population age categories (n = 95)
Age ≤ 62 Age ≥ 63
n Mean SD N Mean SD t p
Physical wellbeing 50 17.43 6.26 45 18.65 7.22 0.148 0.38
Social wellbeing 50 19.73 6.36 45 22.35 5.96 −2.065 0.042*
Emotional wellbeing 50 16.86 4.12 45 17.32 5.93 0.730 0.66
Functional wellbeing 50 15.20 6.63 45 18.70 6.52 −2.950 0.011*
FACT-G 50 69.22 17.34 44 77.18 17.27 −2.227 0.028*
*p < 0.05.
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Research has highlighted the long-term nature of a num-
ber of symptoms associated with cancer treatment, mak-
ing it important to address the ongoing health of those
patients and survivors who may exhibit better physical
coping in the short term. Locality, lack of information and
accessibility could be barriers for patients accessing sup-
port services when they are no longer receiving treatment
or are mulitple years post treatment.
In this population, musculoskeletal symptoms helped
to explain 25% of the variance in respondents’ score on
the PCS (r = −0.501) and 27% of the score on the PWB
scale (r = −0.521) of the FACT-G. This demonstrates the
importance of addressing symptom distress as part of
ongoing patient care. Whether the musculoskeletal symp-
toms are a result of the cancer itself, treatments, or
comorbidities such as arthritis or age-related decline, long-
term management strategies in addition to acute use of
CIT need to be encouraged.
Physical activity is a lifestyle intervention that research
has shown to be safe and effective for alleviating many
of the negative side effects of cancer and its treatments
[21], however 50% of this population had low activity
levels and did not meet current health recommendations.
Research by Blanchard and colleagues (2004) found that
cancer survivors who met more than one lifestyle recom-
mendation reported better QoL than those who met only
one [22]. A potential explanation for this may be that can-
cer patients believe by engaging in multiple lifestyle strat-
egies that they will reduce their risk of recurrence and
increase their sense of control, both of which may im-
prove subjective or percieved QoL. With this in mind our
population may further improve their outcomes through
combining CIT with other lifestyle recommendations such
as increased physical activity.
This research was designed as an exploratory study
conducted over a single five day period at a series of pa-
tient support centres with participants completing a ques-
tionnaire on an isolated occasion. Therefore, there was no
assessment of the impact of specific CIT or any changes
from the initiation of contact with the centres. Future re-
search should assess PROs before and after receiving
support at integrative oncology centres, in addition to the
assessment of the impact of individual therapies. Given the
importance of the relationship between doctor and patient,
and the low disclosure rates regarding CIT, future research
should also incorporate further exploration of the experi-
ences of medical professionals and the integration of
supportive services within traditional medical systems.
Additionally, with the majority of respondents being
women, despite equally high rates of cancer in males, it is
important for support services to be directed towards men
Table 4 Inter-correlations within the muscle and joint
measure (MJM) (n = 95)
Measure Muscle joint measure total score & subscales*
Total Arthralgias Myalgias Cramps
Arthralgias .765 -
Myalgias .860 .544 -
Cramps .669 .331 .424 -
Weakness .834 .466 .688 .453
*All p ≤ .001.
Table 5 Pearson correlations between measures of physical functioning through patient rated outcomes and
musculoskeletal symptoms (n = 95)
Muscle joint measure total scores and subscales
Cramps Arthralgias Myalgias Weakness Total score
SF-36:
General health -.159 -.305** -.282** -.393** -.318**
Bodily pain -.258* -.517** -.448** -.359** -.451**
Role physical -.179 -.357** -.467** -.444** -.422**
Physical functioning -.232* -.513** -.445** -.455** -.490**
Vitality -.044 -.194 -.250** -.344** -.273**
Physical component Score -.235* -.511** -.488** -.463** -.501**
Mental component score -.080 -.118 -.158 -.241* -.192
Schwartz cancer fatigue scale .246* .054 .024 .091 .121
FACT-G: -.205 -.341** -.410** -.405** -.440**
Physical wellbeing -.324** -.398** -.518** -.548** -.574**
Functional wellbeing -.124 -.229* -.319** -.318** -.321**
Social wellbeing -.092 -.079 -.173 -.121 -.149
Emotional wellbeing -.026 -.292** -.137 -.148 -.200
*p < .005, **p < .001 2-tailed.
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and the medical professionals involved in their treatment.
This should be considered in future research and service
provision. Despite two members of the research team be-
ing affiliated with SolarisCare they had no direct impact
with participants or significant involvement in data collec-
tion therefore presenting no potential influence of findings.
Conclusions
The aims of this study were to determine medical and
demographic characteristics of patients accessing support
services at integrative oncology centres across Western
Australia. Key findings from the study included: (a) a large
proportion of the sample (80%) had at least one other
comorbid condition, (b) QoL was significantly lower than
comparative populations, (c) half of the sample were not
meeting recommended physical activity guidelines, and (d)
significantly poorer outcomes were reported for those in
the younger age group, despite no differences for gender.
A greater understanding of the health profiles of pa-
tients presenting to supportive care centres and their
use of CIT, provides health professionals with key infor-
mation to ensure the safety of supportive care practices, as
well as fosters optimal patient outcomes and enhances the
integration of supportive care strategies within main-
stream medical care.
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